Kronos Bio Announces Pricing of Initial Public Offering
Kronos Bio, a clinical-stage biopharmaceutical company, has priced its initial public offering (IPO) of 13,157,895 shares at $19.00 per share, aiming to raise approximately $250 million before expenses. The shares are set to trade on the Nasdaq Global Select Market under the symbol 'KRON' starting October 9, 2020, with the offering expected to close on October 14, 2020. The company has granted underwriters a 30-day option to purchase an additional 1,973,684 shares. Goldman Sachs, Jefferies, Cowen, and Piper Sandler are leading the offering.
- IPO priced at $19.00 per share, raising approximately $250 million.
- Shares to trade on Nasdaq under symbol 'KRON'.
- Underwriters have an option to buy 1,973,684 additional shares, potentially increasing proceeds.
- None.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the pricing of its initial public offering of 13,157,895 shares of its common stock at a price to the public of
The shares are expected to begin trading on the Nasdaq Global Select Market on October 9, 2020, under the ticker symbol “KRON.” The offering is expected to close on October 14, 2020, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Jefferies, Cowen and Piper Sandler are acting as joint book-running managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on October 8, 2020. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a written prospectus, forming a part of the effective registration statement. Copies of the final prospectus relating to the initial public offering may be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at 866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388, or by email at Prospectus_Department@Jefferies.com; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. The company has headquarters in San Mateo, Calif., and a research facility in Cambridge, Mass.
Contact:
Stephanie Yao
Executive Director, Investor Relations and Corporate Communications
650-502-6605
media@kronosbio.com
FAQ
What is the IPO price for Kronos Bio?
How much money is Kronos Bio expected to raise from the IPO?
When will Kronos Bio's shares start trading?
What is the ticker symbol for Kronos Bio?
When is the closing date for Kronos Bio's IPO?
